Target intelligence / Profile preview

Viral antigen presented on major histocompatibility complex class I molecule

Molecular classification
Other, Peptide-MHC complex (not a classical receptor, enzyme, or channel)
01

Overview

A "viral antigen presented on major histocompatibility complex class I molecule" refers to a peptide fragment derived from a viral protein generated within an infected cell, which is displayed on the cell surface by a class I major histocompatibility complex (MHC-I) molecule. All nucleated cells express MHC-I and use this pathway to present antigens from intracellular pathogens, including viruses, to cytotoxic T lymphocytes (CD8+ T cells). Recognition of these viral peptide-MHC-I complexes by T cells is crucial for the adaptive immune response, as it leads to the targeted elimination of infected cells. Many successful viruses evade immune clearance by interfering with the MHC-I antigen presentation pathway. While this "target" is not a single protein or gene, but rather a specific cell-surface complex formed during infection, it is an established focus for immunotherapies, such as engineered T cells or vaccines targeting defined peptide-MHC-I complexes. Notes on correctness: - The phrase describes a complex (peptide + MHC-I), not a standard, fixed molecule, gene, or protein. - It is not the name of a unique, canonical therapeutic target, but refers generically to the immunological phenomenon central to antiviral immune responses. - As a "target," it is valid in immunotherapy and virology, but as a database entity may be flagged as too broad, underspecified, or missing essential disambiguation (i.e., which viral antigen, which HLA allele). If structured data is required (such as for database curation), this entry should be normalized to specific viral peptide-MHC class I complexes (with viral epitope and HLA allele specified) wherever possible.

Other names
Viral antigen-MHC-I complexViral peptide-MHC class I complexVirus-derived peptide presented by MHC class I
02

Mechanism of action

Recognition and binding by cytotoxic CD8+ T cells leading to targeted cell killing. Targeting by engineered T cell receptors or TCR-mimic antibodies (in experimental or therapeutic contexts).

03

Biological functions

Immune responseAntigen presentation to cytotoxic T cells (CD8+)Marking virus-infected cells for destruction
04

Disease associations

InfectionCancer (in the context of altered antigen presentation or immune escape)Other (as relevance depends on specific viral infection or immune response context)
05

Safety considerations

Potential for off-target immune responses or autoimmunity due to similarity between viral and self-peptidesImmune escape through downregulation or loss of MHC class I presentation in infected or tumor cellsHeterogeneity of antigen peptides among patients and viruses limits universal targeting
06

Interacting drugs

Null (no conventional small molecule drugs directly target viral antigens presented on MHC-I, but certain immunotherapies, such as T cell therapies, are designed to recognize these complexes)
07

Biomarkers

Expression of specific viral peptide-MHC class I complexes can be used as biomarkers for viral infection or tumor neoantigen presentation, but there is no single universal biomarker. Rather, the specific peptide-MHC complex serves as a disease-state marker.

Beyond the preview

Go deeper on Viral antigen presented on major histocompatibility complex class I molecule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viral antigen presented on major histocompatibility complex class I molecule.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call